T-cell receptor gamma variable 9 (TRGV9) (TRGV9)

The T-cell receptor gamma variable 9 (TRGV9) chain is a defining component of the Vγ9Vδ2 T-cell receptor, which is the most prevalent gamma-delta TCR subset in human peripheral blood, accounting for approximately 95% of circulating gamma-delta T cells (NIH, 2021). This receptor is unique because it recognizes non-peptide phosphoantigens (pAgs), such as isopentenyl pyrophosphate (IPP), which are produced by the mevalonate pathway in eukaryotes or the MEP pathway in many pathogens (Frontiers in Immunology, 2021). The Vγ9 chain specifically interacts with the butyrophilin 2A1 (BTN2A1) protein, which acts as a sensor for intracellular pAg accumulation alongside BTN3A1 (UniProt Q99603). This interaction triggers the rapid activation of Vγ9Vδ2 T cells, leading to the secretion of pro-inflammatory cytokines like IFN-gamma and TNF-alpha, and the direct lysis of infected or transformed cells (GeneCards). In the context of disease, Vγ9Vδ2 T cells play a vital role in immunosurveillance against various cancers, including solid tumors and hematologic malignancies like acute myeloid leukemia (AML) and multiple myeloma (MM), as well as infectious diseases such as tuberculosis and malaria (NIH, 2021). Therapeutic strategies targeting this receptor include the use of aminobisphosphonates like zoledronic acid to increase intracellular pAg levels, agonistic antibodies against the BTN3A complex such as ICT01, and bispecific T-cell engagers like LAVA-051 and LAVA-1207 that directly bind the TCR to redirect cytotoxicity toward tumor-associated antigens (ImCheck Therapeutics, 2021; LAVA Therapeutics, 2022). These approaches aim to exploit the MHC-independent nature of Vγ9Vδ2 T cells, potentially offering a broader and safer therapeutic window compared to conventional alpha-beta T-cell therapies (Frontiers in Immunology, 2021).

Other names

Vγ9Vgamma9TCRGV9T-cell receptor gamma variable 9V2TRGV9 chainT-cell receptor gamma variable region V9

Activation of Vγ9Vδ2 T cells through direct binding to the TCR or indirect modulation of the butyrophilin (BTN3A1/BTN2A1) complex to induce T-cell mediated lysis of target cells.